Study guide
12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
BCEMP Board Certified Emergency Medicine Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals
1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access
2 Chapter 2: Cardiac Arrest and Dysrhythmias
2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)
3 Chapter 3: Shock and Hemodynamic Resuscitation
3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols
4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)
4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation
5 Chapter 5: Neurocritical Care and Neurologic Emergencies
5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies
6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure
6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure
7 Chapter 7: Pulmonary and Allergic Emergencies
7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols
8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses
8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)
9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes
9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST
10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology
10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome
11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies
11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT
12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship
12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics
13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH
14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness
14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles
15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation
15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED
16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery
16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling
17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry
17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose
18 Chapter 18: Special Populations, Medication Access, and Professional Practice
18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)
12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
Key Takeaways Explain This Topic AI
Emergency department antimicrobial stewardship programs (ASPs) utilize indication-specific CPOE order sets, pharmacist review, and diagnostic integration to optimize empiric therapy while reducing broad-spectrum overuse.
Rapid blood culture identification (BCID) panels and MALDI-TOF enable identification of organisms and critical resistance determinants (mecA, vanA/vanB, carbapenemases) within 1-2 hours of culture positivity, facilitating targeted de-escalation 24-48 hours ahead of standard phenotypic susceptibility.
Serum procalcitonin (PCT) kinetics assist clinical decision-making in lower respiratory tract infections; values <0.25 mcg/L strongly discourage antimicrobial initiation, while levels >=0.5 mcg/L suggest bacterial infection.
Pharmacist-managed post-discharge culture callback programs review positive urine and blood cultures, systematically resolving discordant empiric therapy, intercepting adverse drug reactions, and mitigating inappropriate discharge fluoroquinolones.
Cross-reactivity between penicillins and modern 3rd- and 4th-generation cephalosporins (ceftriaxone, cefepime) is <1-2% due to disparate R1 side chains rather than the core beta-lactam ring, enabling safe cephalosporin use in non-severe penicillin allergies.
Last updated: October 2026
12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics
Note
Independent BCEMP study resource provided by ExamFinch. Content is organized around emergency medicine pharmacotherapy principles tested on clinical specialist certification examinations.
Core Elements of ED Antimicrobial Stewardship
The emergency department is the main gateway for acute hospital admissions, and many inpatient antimicrobial courses begin with the first dose given in the ED. Because the ED environment is characterized by rapid turnover, diagnostic uncertainty, and high acuity, antimicrobial stewardship programs (ASPs) face unique operational demands.
ED Stewardship Interventions
Indication-Specific CPOE Order Sets : Computerized provider order entry (CPOE) order sets structured by specific clinical syndrome (e.g., severe CAP, pyelonephritis, non-purulent cellulitis, intra-abdominal sepsis) rather than generic drug lists. These order sets integrate standardized renal dosing, weight-based loading regimens, and default duration limits.
Pharmacokinetic / Pharmacodynamic (PK/PD) Optimization : Clinical emergency pharmacists implement evidence-based dosing protocols at the point of care:
Extended-Infusion Beta-Lactams : Administering piperacillin-tazobactam as an extended 4-hour infusion or cefepime over 3-4 hours maximizes the time that unbound serum drug concentrations exceed the minimum inhibitory concentration (fT > MIC), which correlates directly with clinical cure in Gram-negative sepsis.
Weight-Based Vancomycin Loading : Administering 20 to 35 mg/kg IV (maximum 2,000-3,000 mg) in critically ill patients rapidly achieves therapeutic serum concentrations within the initial dosing interval.
Discharge Stewardship : Up to 30% to 50% of outpatient antibiotic prescriptions written in the ED contain errors in drug selection, dose, or duration. Key discharge stewardship initiatives include:
Enforcing short, guideline-concordant durations: 3 days of TMP-SMX or 5 days of nitrofurantoin for uncomplicated cystitis; 5 days of beta-lactam therapy for uncomplicated cellulitis or resolving CAP.
Eliminating Inappropriate Fluoroquinolone Prescriptions : Fluoroquinolones (ciprofloxacin, levofloxacin) carry an FDA boxed warning for disabling, potentially irreversible adverse effects: tendinitis and tendon rupture (particularly the Achilles tendon), peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis. Separate (non-boxed) warnings cover aortic aneurysm and dissection, dysglycemia including hypoglycemic coma, and Clostridioides difficile infection. Fluoroquinolones should be restricted to infections where no safer alternatives exist.
Rapid Blood Culture Identification & Diagnostic Integration
Traditional phenotypic blood culture workflows require 24 to 48 hours for blood culture bottles to flag positive, followed by subculturing, Gram staining, and an additional 24 to 48 hours for automated identification and antimicrobial susceptibility testing (AST). Total turnaround time ranges from 48 to 96 hours.
Rapid Molecular Platforms
Multiplex PCR Panels (e.g., BioFire FilmArray BCID2, GenMark ePlex, Luminex Verigene) : Directly amplify and detect bacterial and fungal pathogens and critical resistance determinants directly from positive blood culture broth within 1 to 2 hours of bottle positivity.
MALDI-TOF Mass Spectrometry : Identifies bacterial species within minutes using matrix-assisted laser desorption/ionization time-of-flight spectral fingerprinting from early subculture pellets.
- Actionable Resistance Markers & ED Stewardship Decision Tree RAPID BLOOD CULTURE IDENTIFICATION (BCID) TARGETS
- ┌─────────────────────────────────────────────────────────────────────────────┐
- │ Gram-Positive Targets & Resistance Determinants │
- │ • mecA / mecC (S. aureus) ──► MRSA (PBP2a) ──► Continue Vanc/Dap; Optimize │
- │ • No mecA (S. aureus) ──► MSSA ──► De-escalate to Cefazolin 2g │
- │ • vanA / vanB (E. faecium)──► VRE (D-Ala-Lac)► Switch to Daptomycin/Linezolid│
- ├─────────────────────────────────────────────────────────────────────────────┤
- │ Gram-Negative Targets & Resistance Determinants │
- │ • blaCTX-M ──► ESBL ──► Carbapenem (Meropenem 1g) │
- │ • blaKPC ──► Carbapenemase──► Ceftazidime-avibactam / Vab │
- │ • blaNDM / blaVIM ──► Metallo-BL ──► Cefiderocol OR CZA + AZT │
- └─────────────────────────────────────────────────────────────────────────────┘
Pathogen & Genetic Marker Molecular Resistance Mechanism Clinical Implication & Immediate Action
Staphylococcus aureus with mecA or mecC Encodes penicillin-binding protein 2a (PBP2a) , which possesses extremely low binding affinity for nearly all beta-lactams. MRSA confirmed . Maintain Vancomycin (target AUC/MIC 400-600) or Daptomycin (8-10 mg/kg IV). Discontinue cefazolin or antistaphylococcal penicillins.
Staphylococcus aureus WITHOUT mecA / mecC Intact, native PBPs without PBP2a expression. MSSA confirmed . Immediately de-escalate Vancomycin to Cefazolin 2 g IV q8h (or Nafcillin/Oxacillin 2 g IV q4h). Clinical studies demonstrate a 30-40% reduction in mortality when MSSA bacteremia is switched from vancomycin to an anti-staphylococcal beta-lactam.
Enterococcus faecium with vanA or vanB Encodes ligases that synthesize D-alanyl-D-lactate in place of D-alanyl-D-alanine peptidoglycan termini, eliminating vancomycin binding. Vancomycin-Resistant Enterococcus (VRE) . Discontinue Vancomycin. Initiate Daptomycin (8-12 mg/kg IV daily) or Linezolid (600 mg IV q12h).
Enterobacterales with blaCTX-M Encodes extended-spectrum beta-lactamase (ESBL) , hydrolyzing 3rd-generation cephalosporins, aztreonam, and cefepime. ESBL-producing Enterobacterales . Discontinue cephalosporins. Switch to a Carbapenem (Meropenem 1 g IV q8h or Ertapenem 1 g IV q24h).
Enterobacterales with blaKPC Class A serine carbapenemase (Klebsiella pneumoniae carbapenemase), hydrolyzing carbapenems, penicillins, and cephalosporins. Carbapenem-Resistant Enterobacterales (CRE) . Standard carbapenems ineffective. Initiate Ceftazidime-avibactam 2.5 g IV q8h or Meropenem-vaborbactam 4 g IV q8h.
Enterobacterales with blaNDM or blaVIM Class B metallo-beta-lactamases (MBLs) utilizing zinc ions to hydrolyze all beta-lactams EXCEPT aztreonam. MBL-producing CRE . Resistant to ceftazidime-avibactam alone. Initiate Cefiderocol 2 g IV q8h OR combination Ceftazidime-avibactam PLUS Aztreonam (avibactam protects aztreonam from co-produced ESBLs/serine beta-lactamases). Aztreonam-avibactam (FDA-approved in 2025 for complicated intra-abdominal infection) packages the same strategy in one product.
Procalcitonin (PCT) in Lower Respiratory Tract Infections
Procalcitonin (PCT) is a 116-amino acid peptide prohormone. Under non-infectious physiological conditions, it is produced in the neuroendocrine C-cells of the thyroid gland, where it is cleaved into calcitonin with undetectable serum levels (<0.05 mcg/L).
Biology of the Host Response
Bacterial Stimulation : In response to systemic bacterial infection, bacterial endotoxin (lipopolysaccharide) and pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6) induce ubiquitous transcription of the CALC-1 gene in all parenchymal tissues (liver, lung, kidney, adipose). Large quantities of procalcitonin are released into circulation, detectable within 2 to 4 hours and peaking at 12 to 24 hours.
Viral Suppression : During systemic viral infections, host T-cells and monocytes secrete interferon-gamma (IFN-gamma) , which selectively blocks and down-regulates CALC-1 gene transcription . Consequently, procalcitonin levels remain low or undetectable during pure viral respiratory infections (e.g., influenza, SARS-CoV-2, RSV, human metapneumovirus).
Clinical Decision Algorithm in LRTIs
- Serum Procalcitonin Level Probability of Bacterial Infection Clinical Antimicrobial Guidance
- <0.10 mcg/L Bacterial infection highly unlikely Antimicrobial initiation strongly discouraged
- 0.10 to 0.24 mcg/L Bacterial infection unlikely Antimicrobial initiation discouraged
- 0.25 to 0.49 mcg/L Bacterial infection likely Antimicrobial initiation encouraged
≥0.50 mcg/L Bacterial infection highly likely Antimicrobial initiation strongly encouraged (indicates invasive bacterial infection or bacteremia)
Clinical Limitations & Confounding Factors
False-Positive Elevations (Non-Infectious Sepsis Mimics) : Severe non-infectious physiological trauma triggers massive parenchymal cytokine release, producing elevated PCT in the absence of bacterial infection. Common false-positive etiologies include: massive mechanical trauma, extensive burn injury, post-cardiac arrest resuscitation (post-resuscitation syndrome), acute ischemic bowel, severe pancreatitis, end-stage renal disease (ESRD on hemodialysis due to decreased renal clearance), and medullary thyroid carcinoma.
False-Negative Results : Early presentation (<4-6 hours from symptom onset; kinetics require 6-12 hours for peak synthesis), localized non-invasive infections (small empyema, localized cutaneous abscess), and atypical intracellular pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae).
Note
Procalcitonin should never override clinical judgment in unstable patients. In septic shock, acute hypoxic respiratory failure, or ICU admission, initiate empiric antimicrobials immediately regardless of initial PCT. Serial PCT measurements obtained 24 to 48 hours later can then guide safe, early antimicrobial de-escalation or discontinuation once stability is achieved.
Post-Discharge Culture and Susceptibility Callback Programs
Urine, blood, sputum, and wound cultures obtained in the emergency department typically finalize 24 to 72 hours after collection, long after the patient has been discharged home. Without systematic follow-up, discordant antimicrobial therapy leads to treatment failures, preventable hospital readmissions, and recurrent ED visits.
Pharmacist-Led Callback Architecture
Emergency medicine pharmacists are uniquely positioned to manage culture callback workflows using electronic health record surveillance queues. The daily callback protocol involves three core review steps:
Evaluation of Culture Results : Review finalized organism identification and in vitro susceptibility profile.
Evaluation of Prescribed Empiric Regimen : Determine whether the prescribed discharge antibiotic is concordant (susceptible), discordant (resistant), or suboptimal (overly broad or subtherapeutic).
Patient Assessment & Intervention :
Bug-Drug Discordance (Resistance) : Contact the patient via telephone. If the patient is asymptomatic and clinically resolved, re-evaluation may be deferred depending on the clinical syndrome; if symptoms persist or worsen, change therapy via an established collaborative practice agreement (CPA) to a targeted, narrow-spectrum agent and electronic-prescribe to their outpatient pharmacy. Instruct the patient to return to the ED if fevers, rigors, flank pain, or altered mentation develop.
Positive Blood Cultures : Any discharged patient with a confirmed pathogenic positive blood culture (e.g., Staphylococcus aureus, Streptococcus pneumoniae, Gram-negative bacilli) represents a clinical emergency requiring immediate direct contact and routing back to the ED for repeat blood cultures, echocardiography, source identification, and IV antimicrobial therapy.
Asymptomatic Bacteriuria (ASB) Interception : Intercepting and discontinuing unnecessary discharge antibiotics in elderly patients with positive urine cultures who presented for non-infectious complaints (e.g., mechanical falls, chronic confusion) and lack true lower urinary tract symptoms.
Antibiotic Allergies in the ED: Penicillin Allergy De-Labeling
Approximately 10% of the United States population reports a penicillin allergy in their electronic health record. However, extensive clinical and immunological studies show that over 90% to 95% of these patients are not truly allergic when subjected to formal testing. Many reported reactions are either non-allergic adverse effects (e.g., childhood nausea, headache, viral exanthem) or represent IgE antibodies that have naturally waned over time (IgE-mediated sensitivity decays by approximately 10% to 20% per year; >80% lose sensitivity after 10 years).
The Clinical Cost of False Allergy Labels
Patients carrying an unverified penicillin allergy label receive significantly more second-line, broad-spectrum agents (vancomycin, fluoroquinolones, clindamycin, aminoglycosides), resulting in:
- A 30% higher risk of Clostridioides difficile colitis
- Higher rates of surgical site infections
- Increased colonization with MRSA and VRE
- Higher rates of acute kidney injury from vancomycin and aminoglycosides
- Longer lengths of stay and elevated healthcare expenditures
- Immunological Cross-Reactivity: R1 Side Chains vs. The Beta-Lactam Ring
Historical dogma taught that penicillins exhibit a 10% cross-reactivity rate across all cephalosporins. This historic estimate was derived from flawed 1960s literature, where early cephalosporin lots were heavily contaminated with trace penicillin during manufacture.
Modern immunological evidence confirms that true IgE-mediated cross-reactivity is determined by structural homology of the R1 side chain , NOT the core four-membered beta-lactam ring: BETA-LACTAM CORE vs. R1 SIDE-CHAIN HOMOLOGY
- Penicillin Core Cephalosporin Core
- ┌────────────────┐ ┌────────────────┐
- R1─┤ β-Lactam │ R1─┤ β-Lactam │─R2
- │ 5-Member Ring │ │ 6-Member Ring │
- └────────────────┘ └────────────────┘
- Thiazolidine Dihydrothiazine
First-Generation Cephalosporins :
Cefazolin : Possesses a unique dihydro-thiadiazole R1 side chain that shares zero structural homology with penicillin, ampicillin, or amoxicillin. True cross-reactivity between penicillin and cefazolin is virtually 0% . Cefazolin is safe to administer in almost all penicillin-allergic patients without history of severe cutaneous adverse reactions.
Cephalexin & Cefadroxil : Share identical or near-identical R1 side chains with ampicillin and amoxicillin, respectively. Cross-reactivity between amoxicillin and cephalexin is approximately 2% to 3%.
Third- and Fourth-Generation Cephalosporins (Ceftriaxone, Cefotaxime, Cefepime) :
Possess an oxyimino aminothiazolyl R1 side chain that is completely structurally distinct from penicillin and aminopenicillins.
True cross-reactivity between penicillin and ceftriaxone, cefotaxime, or cefepime is <1% to 2% (comparable to baseline drug reaction rates in unallergic populations).
Carbapenems (Meropenem, Ertapenem, Imipenem) :
Cross-reactivity between penicillin and carbapenems is <1% .
Monobactams (Aztreonam) :
Aztreonam has a standalone monocyclic beta-lactam ring and exhibits zero cross-reactivity with all penicillins and cephalosporins EXCEPT Ceftazidime (aztreonam and ceftazidime share an identical R1 side chain).
Penicillin Allergy Cross-Reactivity Matrix
Antimicrobial Agent R1 Side Chain Structural Relationship to Penicillin Risk of Cross-Reactivity in Penicillin Allergy ED Clinical Practice Recommendation
Cefazolin (1st gen) Completely distinct (unique dihydro-thiadiazole) <1% (virtually 0%) Safe to administer in non-severe and IgE-mediated penicillin allergies (e.g., surgical prophylaxis, MSSA bacteremia).
Cephalexin (1st gen) Identical to Ampicillin ~2% to 3% Avoid if known ampicillin/amoxicillin allergy; safe if reaction was to penicillin VK or remote uncharacterized rash.
Ceftriaxone (3rd gen) Completely distinct (oxyimino aminothiazolyl) <1% to 2% Safe to administer in non-anaphylactic penicillin allergies (e.g., CAP, pyelonephritis, meningitis, gonococcal infections).
Cefepime (4th gen) Completely distinct (syn-oxyimino aminothiazolyl) <1% to 2% Safe to administer in severe sepsis and neutropenic fever without prior testing.
Meropenem (Carbapenem) Disparate core bicyclic structure <1% Safe to administer in septic shock, ESBL infections, and polymicrobial intra-abdominal sepsis.
Aztreonam (Monobactam) Monocyclic beta-lactam; shares side chain ONLY with Ceftazidime 0% (cross-reacts only with Ceftazidime) Safe across all penicillin allergies. Contraindicated only if documented allergy to Ceftazidime.
The PEN-FAST Decision Tool for ED De-Labeling
The PEN-FAST score is a validated point-of-care clinical decision rule developed to rapidly risk-stratify reported penicillin allergies in adult patients:
- P (Penicillin allergy within past 5 years) : 2 points
- E (Anaphylaxis or Angioedema, OR Severe Cutaneous Adverse Reaction [SCAR: SJS/TEN, DRESS]) : 2 points
- N (Treatment required for allergy episode [epinephrine, steroids, antihistamines, ED visit]) : 1 point
- PEN-FAST Clinical Risk Scoring
- Score 0 : Very low risk (<1% probability of true IgE-mediated allergy)
- Score 1 to 2 : Low risk (<5% probability of true allergy)
- Score ≥3 : Moderate to high risk (≥20% probability of true allergy)
Tip
In patients presenting to the emergency department with a PEN-FAST score of 0 or 1 (e.g., an uncharacterized, non-pruritic childhood rash >10 years ago without systemic symptoms or hospitalization), clinical guidelines support direct administration of 3rd- or 4th-generation cephalosporins (Ceftriaxone, Cefepime) or carbapenems without skin testing or allergy consultation. If an oral challenge is indicated, a single supervised oral dose of amoxicillin 250 mg with 1 hour of observation safely de-labels >95% of low-risk patients.